Adaptimmune Announces Closing of Initial Public Offering
(Thomson Reuters ONE) -
OXFORD, UK and PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Adaptimmune
(Nasdaq:ADAP) today announced the closing of its initial public offering of
11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00
per ADS. The aggregate net proceeds to Adaptimmune, after underwriting discounts
and commissions and estimated offering expenses, were approximately $175.7
million. As previously reported, Adaptimmune has granted the underwriters a 30-
day option to purchase up to an additional 1,687,500 ADSs.
A registration statement relating to these securities was declared effective by
the U.S. Securities and Exchange Commission (SEC) on May 5, 2015.
BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as joint book-
running managers and Guggenheim Securities acted as lead manager for the
offering.
This offering was made only by means of a written prospectus forming part of the
effective registration statement. A copy of the final prospectus related to the
offering was filed with the SEC on May 7, 2015 and may be obtained at no cost by
visiting EDGAR on the SEC's website (www.sec.gov), or from: BofA Merrill Lynch,
222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by email at
dg.prospectus_requests(at)baml.com; Cowen and Company, LLC, c/o Broadridge
Financial Services, Attention: Prospectus Department, 1155 Long Island
Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or
Leerink Partners LLC, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, MA 02110, by email at syndicate(at)leerink.com, or by phone at
(800) 808-7525 ext. 6142.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of such state or
jurisdiction.
This communication is being directed only at (i) persons who are outside the
United Kingdom or (ii) persons who have professional experience in matters
relating to investments who fall within Article 19(5) ("Investment
professionals") of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order") or (iii) certain high value persons and
entities who fall within Article 49(2)(a) to (d) ("High net worth companies,
unincorporated associations etc.") of the Order; or (iv) any other person to
whom it may lawfully be communicated (all such persons in (i) to (iv) together
being referred to as "relevant persons"). The ADSs are only available to, and
any invitation, offer or agreement to subscribe, purchase or otherwise acquire
such ADSs will be engaged in only with, relevant persons. Any person who is not
a relevant person should not act or rely on this document or any of its
contents.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel
cancer immunotherapy products based on its T-cell receptor platform. Established
in 2008, the company aims to utilize the body's own machinery - the T cell - to
target and destroy cancer cells by using engineered, increased affinity T cell
receptors (TCRs) as a means of strengthening natural patient T cell responses.
Adaptimmune's lead program is an affinity enhanced TCR therapeutic targeting the
NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated
signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in
hematologic cancer types. In June 2014, Adaptimmune announced that it had
entered into a strategic collaboration and licensing agreement with
GlaxoSmithKline for the development and commercialization of the NY-ESO TCR
program. The Company currently has over 100 employees.
CONTACT: Adaptimmune Contact
Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mob: +44 (0)7710 304249
E: margaret.henry(at)adaptimmune.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Adaptimmune LLC via GlobeNewswire
[HUG#1920678]
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2015 - 18:14 Uhr
Sprache: Deutsch
News-ID 392306
Anzahl Zeichen: 4958
contact information:
Town:
Philadelphia
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Adaptimmune Announces Closing of Initial Public Offering"
steht unter der journalistisch-redaktionellen Verantwortung von
Adaptimmune LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
